66 related articles for article (PubMed ID: 8144976)
1. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide.
Kelker HC; Schlesinger D; Valentine FT
J Immunol; 1994 Apr; 152(8):4139-48. PubMed ID: 8144976
[TBL] [Abstract][Full Text] [Related]
2. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL
J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123
[TBL] [Abstract][Full Text] [Related]
3. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
4. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
Akerblom L; Nara P; Dunlop N; Putney S; Morein B
Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
[TBL] [Abstract][Full Text] [Related]
5. Simple strategy to induce antibodies of distinct specificity: application to the mapping of gp120 and inhibition of HIV-1 infectivity.
Prieto I; Hervás-Stubbs S; García-Granero M; Berasain C; Riezu-Boj JI; Lasarte JJ; Sarobe P; Prieto J; Borrás-Cuesta F
Eur J Immunol; 1995 Apr; 25(4):877-83. PubMed ID: 7737288
[TBL] [Abstract][Full Text] [Related]
6. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein.
Benjouad A; Mabrouk K; Gluckman JC; Fenouillet E
FEBS Lett; 1994 Mar; 341(2-3):244-50. PubMed ID: 8137947
[TBL] [Abstract][Full Text] [Related]
7. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
8. N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.
Sjölander S; Bolmstedt A; Akerblom L; Horal P; Olofsson S; Morein B; Sjölander A
Virology; 1996 Jan; 215(2):124-33. PubMed ID: 8560759
[TBL] [Abstract][Full Text] [Related]
9. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
11. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
[TBL] [Abstract][Full Text] [Related]
12. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
Fenouillet E; Miquelis R; Drillien R
Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
[TBL] [Abstract][Full Text] [Related]
13. Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins.
Gorny MK; VanCott TC; Williams C; Revesz K; Zolla-Pazner S
Virology; 2000 Feb; 267(2):220-8. PubMed ID: 10662617
[TBL] [Abstract][Full Text] [Related]
14. Immune response to human immunodeficiency virus. In vivo administration of anti-idiotype induces an anti-gp160 response specific for a synthetic peptide.
Zhou EM; Chanh TC; Dreesman GR; Kanda P; Kennedy RC
J Immunol; 1987 Nov; 139(9):2950-6. PubMed ID: 3668251
[TBL] [Abstract][Full Text] [Related]
15. Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120.
Thiriart C; Francotte M; Cohen J; Collignon C; Delers A; Kummert S; Molitor C; Gilles D; Roelants P; van Wijnendaele F
J Immunol; 1989 Sep; 143(6):1832-6. PubMed ID: 2476484
[TBL] [Abstract][Full Text] [Related]
16. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
17. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
Shirai M; Pendleton CD; Ahlers J; Takeshita T; Newman M; Berzofsky JA
J Immunol; 1994 Jan; 152(2):549-56. PubMed ID: 8283036
[TBL] [Abstract][Full Text] [Related]
18. [Localization of the HIV-1 gp120 conformational epitope recognized by virus neutralizing monoclonal antibodies 2G12].
Tumanova OIu; Kuvshinov VN; Il'ichev AA; Nekrasov BG; Ivanisenko VA; Kozlov AP; Sandakhchiev LS
Mol Biol (Mosk); 2002; 36(4):657-63. PubMed ID: 12173470
[TBL] [Abstract][Full Text] [Related]
19. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain.
Deml L; Kratochwil G; Osterrieder N; Knüchel R; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):10-25. PubMed ID: 9300033
[TBL] [Abstract][Full Text] [Related]
20. Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.
Vu HM; de Lorimier R; Moody MA; Haynes BF; Spicer LD
Biochemistry; 1996 Apr; 35(16):5158-65. PubMed ID: 8611499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
